Overview

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

Status:
Completed

Trial end date:
2017-03-28

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and tolerability profile of BFKB8488A following subcutaneous (SC) administration in overweight and obese participants (body mass index [BMI] greater than [>] 27 to less than or equal to [Phase: Phase 1

Details

Lead Sponsor:

Genentech, Inc.